Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ono, PD-1 Discoverer Settle Long-Running Patent Dispute

Includes $200m Gift To Foundation

Executive Summary

Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund. 

You may also be interested in...



Champagne Flows As CTLA-4/PD-1 Pioneers Allison And Honjo Win Nobel Prize

Joint prize for MD Anderson's James Allison and Kyoto University's Tasuku Honjo for checkpoint immunotherapy reflects decades of research and billions of IO dollars for industry.

Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds

Bristol-Myers Squibb has taken a beating over setbacks for its Opdivo and its immuno-oncology portfolio, but a settlement reached with Merck over Keytruda’s patent infringement is a momentary victory for the PD-1 pioneer.

APAC Podcast: Policies Play Out Against Pandemic, Corporate Activity Remains Strong

Join the Asia Pacific content team for a wide-ranging overview and analysis of recent developments across China, India, South Korea and Japan in the policy, regulatory, commercial and vaccines spaces over the past few months. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC145439

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel